PSMC6 as A Therapeutic Target for Cirrhosis and Liver Cancer (G5706)

Target Name: PSMC6

NCBI ID: G5706

PSMC6

PSMC6 as A Therapeutic Target for Cirrhosis and Liver Cancer

PSMC6 (threonine-binding transfer glycoprotein 6) is a glycoprotein that is normally produced by the liver and excreted from the intestine primarily by bile. However, the expression level of PSMC6 changes in liver diseases such as cirrhosis and liver cancer, making it an important therapeutic target for these diseases.

PSMC6, as a glycoprotein, has multiple biological functions. The most significant of these is its metastatic effect in the liver. In patients with cirrhosis, the expression level of PSMC6 increases, which makes them more likely to metastasize from the liver to other tissues and organs, thereby aggravating disease progression and patient survival risks. Therefore, reducing the expression level of PSMC6 is an important goal in the treatment of cirrhosis and liver cancer.

PSMC6 is also immunogenic and can activate the immune system and induce immune cells to release cytokines and antibodies. This immunogenicity makes PSMC6 a potential drug target for the treatment of autoimmune diseases and other immune-related diseases.

The expression level of PSMC6 in liver diseases is also closely related to hepatocyte damage and treatment response. Studies have shown that the expression level of PSMC6 can be used as an important indicator to evaluate the degree of liver cell damage and treatment response. In addition, the expression level of PSMC6 can also predict patient survival risk and provide guidance for patients with personalized treatment plans.

As a glycoprotein, PSMC6 has multiple biological functions in liver diseases and is therefore considered a potential drug target. Reducing the expression level of PSMC6 can be used to treat cirrhosis and liver cancer, and can be used to assess disease severity and predict patient survival risk. Future research can further explore the mechanism of PSMC6 in liver diseases and provide patients with better treatment options.

Protein Name: Proteasome 26S Subunit, ATPase 6

Functions: Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair. PSMC6 belongs to the heterohexameric ring of AAA (ATPases associated with diverse cellular activities) proteins that unfolds ubiquitinated target proteins that are concurrently translocated into a proteolytic chamber and degraded into peptides

The "PSMC6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PSMC6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets